Taisho Pharmaceutical Co., Ltd.

Meiji Seika Pharma Co., Ltd.

Meiji Seika Kaisha, Ltd.

Naoki Sasamoto

Masato Kashimura

Tomoaki Miura

Tomohiro Sugimoto

Kenichi Kanemoto

Kanako Yamamoto

Jun Kurosaka

Eiki Shitara

Haruhisa Ogita

Kou Kumura

Ken Chikauchi

Tomohiro Ozawa

Satoshi Yoshida

Masato Hayashi

Keiichi Ajito

Keiji Tamura

Dai Kubota

Yasunobu Ushiki

Madoka Kawamura

Akira Manaka

A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas). 

C-4&#x2033; position substituted macrolide derivative

A 10-azalide compound having a 4-membered ring structure crosslinked at the 10- and 12-positions, which is represented by the formula (I), and is effective on even, or erythromycin resistant bacteria (e.g., resistant pneunococci and streptococci). 

10a-azalide compound having 4-membered ring structure

A novel 10a-azalide compound crosslinked at the 10a- and 12-positions, which is represented by the following formula, and is effective on even, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci). 

10a-Azalide compound crosslinked at 10a- and 12-positions

[Object]: To provide a compound having a novel structure effective againstand erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

10a-Azalide compound

Growing community of inventors

Saitama, Japan

Naoki Sasamoto